2013
Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: A descriptive study
Publication
Publication
Expert Opinion on Drug Safety , Volume 12 - Issue 1 p. 29- 38
Objective: Three online surveys explored compliance with the PPP by pharmacists and dermatologists, in the Netherlands. In 2007 and 2011, two pharmacist surveys were conducted to assess improvement over time. Methods: In 2007, survey was sent to members of the Utrecht Pharmacy Panel for Education & Research (UPPER) network (n = 1000) and in 2011, to the research group of the Dutch Association of Pharmacists (KNMP) (n = 556). In 2010, a survey was sent to 564 dermatologists of the Dutch Association of Dermatology and Venereology (NVDV). Results: Both pharmacists' questionnaires had response rates of 20% and the dermatologist questionnaire of 28%. Pharmacists' checks on 30-day dispensing remained 82%, but a check whether the prescription is out-of-date decreased (61 to 53%). Pharmacists asked the patient for a negative pregnancy test in 15%, but use of contraception was checked by 44 - 49%. One hundred and five dermatologists (64%) always prescribe contraception; 35 (22%) occasionally. Ninety-three percent of the dermatologists were of the opinion that they performed the PPP. Analysis of different elements of the PPP showed that 41 (25%) were compliant. Conclusions: The observed non-Adherence to the isotretinoin PPP calls for careful evaluation of risk minimisation plans and participation of all stakeholders in the development of these plans.
Additional Metadata | |
---|---|
, , , , , | |
doi.org/10.1517/14740338.2013.745850, hdl.handle.net/1765/68912 | |
Expert Opinion on Drug Safety | |
Organisation | Department of Intensive Care |
Crijns, I, Mantel-Teeuwisse, A.K, Bloemberg, R, Pinas, E, Straus, S.M.J.M, & de Jong-van den Berg, L.T.W. (2013). Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: A descriptive study. Expert Opinion on Drug Safety (Vol. 12, pp. 29–38). doi:10.1517/14740338.2013.745850
|